Not provided
Not provided
Not provided
Not provided
Not provided
Low Recruitment rate
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Medical University Innsbruck | OTHER |
| International Medical Research - Partner GmbH | OTHER |
| dsh statistical services GmbH | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine the efficacy and safety of a diabetes-specific tube feed in comparison to an isocaloric, isonitrogenous standard enteral formula in critically ill patients receiving insulin treatment for blood glucose management.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Diben 1.5 kcal HP | Other | Diben 1.5 kcal HP, Food for Special Medical Purposes (diabetes-specific tube feed) |
|
| Fresubin HP Energy Fibre (1.5 kcal) | Other | Fresubin HP Energy Fibre (1.5 kcal), Food for Special Medical Purposes (standard tube feed) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Diben 1.5 kcal HP | Other | Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (CharriƩre (CH) > 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day). |
| Measure | Description | Time Frame |
|---|---|---|
| Blood glucose variability (within patient standard deviation of blood glucose values per day) | At Day 3 of intervention or the day prior to switch from intravenous to subcutaneous insulin administration, whichever comes first |
| Measure | Description | Time Frame |
|---|---|---|
| Glucose variability | Days 2, 4 and 5 of intervention | |
| Time to switch from intravenous to subcutaneous insulin administration | Days 1-6, daily | |
| Insulin requirements in IU per day |
Not provided
Inclusion Criteria:
Patients with spontaneous aneurysmal subarachnoid hemorrhage (SAH) defined according to Hunt and Hess scale grade HH5
Requiring mechanical ventilation in the ICU at the time of enrolment
Enteral nutrition (EN) in the ICU at time of enrolment
Patients expected to stay in the ICU for at least 5 days following enrolment
Age 18 - 75 years
Glycemic control with intravenous insulin therapy to maintain a target glucose range between 110 mg/dL and 150 mg/dL (6.1 and 8.3 mmol/l)
Informed consent according to local regulations for decisionally impaired subjects
Exclusion Criteria:
Exclusion After Enrolment (Withdrawal of Subjects)
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ronny Beer, PD Dr. med. | Medical University of Innsbruck, Department of Neurology, Neurocritical Care Unit | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UniversitƤtsklinikum Innsbruck | Innsbruck | 6020 | Austria |
Not provided
| ID | Term |
|---|---|
| D013345 | Subarachnoid Hemorrhage |
| D003920 | Diabetes Mellitus |
| D007333 | Insulin Resistance |
| ID | Term |
|---|---|
| D020300 | Intracranial Hemorrhages |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Fresubin HP Energy Fibre (1.5 kcal) | Other | Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (CharriƩre (CH) > 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day). |
|
| Days 1 - 6, daily |
| Blood glucose levels | Days 1 - 6, daily |
| HbA1c | Days 1, 6, 28 |
| Difference between target and given enteral nutrition (Compliance) | Days 2-6, daily |
| Cerebral and subcutaneous microdialysis: glucose | Days 1 - 6, daily |
| Cerebral and subcutaneous microdialysis: lactate/pyruvate ratio | Days 1 - 6, daily |
| Hospital mortality | Day 28 |
| ICU mortality | Day 28 |
| ICU length of stay | Day 28 |
| Days of mechanical ventilation | Day 28 |
| Non-gastrointestinal complications (AEs) to enteral nutrition and application | Days 2-6, daily |
| Gastro-intestinal intolerance (AEs, complications) | Days 2-6, daily |
| D009422 | Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D006470 | Hemorrhage |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D006946 | Hyperinsulinism |